Schizophrenia and the broader family of psychotic disorders — schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, substance/medication-induced psychotic disorder, and psychotic disorder due to another medical condition — are serious, often chronic mental illnesses that affect approximately 1% of Canadians lifetime. They are also the single clearest near-absolute contraindication to most forms of psychedelic-assisted therapy as currently studied. This article is a safety-focused Canadian guide explaining why a personal or first-degree family history of schizophrenia, schizoaffective disorder, or other primary psychotic disorder is a standard exclusion criterion across virtually every published psychedelic-assisted therapy RCT (Goodwin 2022; Mitchell 2021/2023; Carhart-Harris 2021; Bogenschutz 2022). The mechanistic rationale is concrete: classical psychedelics (psilocybin, LSD) act as 5-HT2A receptor agonists, the same receptor system implicated in psychotomimetic effects; MDMA combines serotonergic and dopaminergic release; ketamine is an NMDA-receptor antagonist that produces dissociative and frankly psychotomimetic effects even in healthy controls. In a person with a psychotic-disorder diagnosis or genetic vulnerability, these mechanisms can precipitate, prolong, or worsen psychotic symptoms.

Key takeaways

Schizophrenia and primary psychotic disorders affect roughly 1% of Canadians lifetime; first-episode typically presents in late adolescence to early adulthood.

Personal history of any primary psychotic disorder is a near-absolute exclusion across psilocybin, MDMA, and most ketamine RCTs (Goodwin 2022; Mitchell 2021/2023; Carhart-Harris 2021; Bogenschutz 2022).

First-degree family history of schizophrenia or schizoaffective disorder (parent, full sibling, or child) is also a standard exclusion in psilocybin and MDMA trials due to elevated genetic vulnerability.

Mechanistic reason: 5-HT2A agonism (psilocybin, LSD) and NMDA antagonism (ketamine) can produce psychotomimetic phenomena; MDMA's serotonergic/dopaminergic release adds further risk.

First-line treatment is foundational and non-negotiable: antipsychotics (clozapine for treatment-resistant schizophrenia; risperidone, olanzapine, aripiprazole, paliperidone), CBT for psychosis, family intervention, supported employment, and assertive community treatment.

Health Canada Spravato product monograph lists psychotic disorder as a relevant caution; off-label generic ketamine in psychotic-spectrum patients is rarely clinically appropriate.

Self-medication risk is real: prodromal patients sometimes use unsupervised psychedelics, which can accelerate or unmask psychotic illness.

Comprehensive intake screening is essential at every psychedelic-assisted therapy program, including direct questions about prior psychotic episodes (substance-induced included) and first-degree family history.

Defining the psychotic disorder spectrum

The DSM-5 chapter "Schizophrenia Spectrum and Other Psychotic Disorders" includes:

Schizophrenia: ≥6 months of disturbance with ≥1 month of active-phase symptoms (delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behaviour, negative symptoms); significant social/occupational dysfunction.
Schizoaffective disorder: schizophrenia symptoms plus a major mood episode (depressive or manic) for the majority of illness duration, with ≥2 weeks of psychotic symptoms in the absence of a mood episode.
Schizophreniform disorder: schizophrenia-like symptoms lasting 1–6 months.
Brief psychotic disorder: ≥1 day to <1 month of psychotic symptoms with full return to premorbid function.
Delusional disorder: ≥1 month of delusions without other prominent psychotic features.
Substance/medication-induced psychotic disorder: psychotic symptoms attributable to a substance (including, notably, hallucinogens, stimulants, cannabis).
Psychotic disorder due to another medical condition: e.g., temporal-lobe epilepsy, autoimmune encephalitis, Huntington's disease.

Treatment-resistant schizophrenia (TRS) — failure of ≥2 adequate antipsychotic trials — has a defined gold-standard pharmacotherapy: clozapine.

First-line, evidence-based treatment is foundational

Before any consideration of off-label or research-protocol interventions, evidence-based care for psychotic disorders includes:

Antipsychotics: risperidone, olanzapine, aripiprazole, paliperidone, lurasidone, quetiapine, ziprasidone; long-acting injectables (LAIs) for adherence-sensitive patients.
Clozapine for TRS: the only antipsychotic with demonstrated superiority in treatment-resistant schizophrenia; requires hematologic monitoring (agranulocytosis risk).
CBT for psychosis (CBTp): structured psychotherapy with the strongest psychosocial evidence base in schizophrenia.
Family intervention: psychoeducation and communication-focused work demonstrably reduces relapse.
Supported employment / education: Individual Placement and Support (IPS) model.
Assertive Community Treatment (ACT) and Early Psychosis Intervention (EPI) services across Canadian provinces.
Comorbid substance use treatment: tightly integrated, given high prevalence and outcome impact.

CANMAT, the Canadian Psychiatric Association, and provincial Early Psychosis Intervention guidelines uniformly position antipsychotic pharmacotherapy plus psychosocial intervention as first-line. Psychedelic-assisted therapy is not part of any current Canadian clinical practice guideline for psychotic disorders.

Why psychedelic-assisted therapy is generally contraindicated

Mechanism — 5-HT2A agonism (psilocybin, LSD)

Classical psychedelics produce their characteristic perceptual and cognitive effects primarily through agonism at the serotonin 5-HT2A receptor. This same receptor system has been implicated in psychotomimetic phenomena. The relationship between 5-HT2A signalling and the dopaminergic dysregulation central to schizophrenia is part of why 5-HT2A antagonism is a feature of several second-generation antipsychotics. Administering a 5-HT2A agonist to a person with a psychotic disorder runs in the opposite mechanistic direction from established antipsychotic pharmacology.

In healthy volunteers, psilocybin and LSD reliably produce transient phenomena that resemble psychotic symptoms — perceptual distortions, ego dissolution, occasional paranoid ideation. In a person with schizophrenia, schizoaffective disorder, or genetic vulnerability, the safety profile is qualitatively different.

Mechanism — MDMA serotonergic and dopaminergic release

MDMA produces robust release of serotonin, noradrenaline, and dopamine, with downstream 5-HT2A activity. Mitchell 2021/2023 and Mithoefer 2018 explicitly excluded primary psychotic disorders from PTSD trials, and post-trial analyses have not changed that exclusion.

Mechanism — NMDA antagonism (ketamine, esketamine)

Ketamine is a non-competitive NMDA-receptor antagonist. Its dissociative and psychotomimetic effects in healthy volunteers have, for decades, served as one of the foundational pharmacological models of schizophrenia in research (Krystal et al.). Importantly, dissociative phenomena during a ketamine session — depersonalization, derealization, perceptual changes — are not benign in someone with a psychotic-disorder history; they may precipitate or amplify symptoms.

The Health Canada Spravato (esketamine) product monograph flags psychotic disorder as a relevant caution, and clinical practice in Canadian Spravato programs reflects this. Off-label generic ketamine carries the same mechanistic concern; most Canadian KAP clinics treat psychotic-disorder history as an exclusion or near-exclusion.

First-degree family history — genetic vulnerability

Schizophrenia is among the most heritable major psychiatric illnesses. A first-degree relative (parent, full sibling, child) with schizophrenia or schizoaffective disorder substantially elevates lifetime risk relative to the general population. RCTs in psilocybin (Goodwin 2022 COMP001; Carhart-Harris 2021 NEJM) and MDMA-AT (Mitchell 2021/2023) routinely list first-degree family history of schizophrenia or other primary psychotic disorder as an exclusion criterion. This is not arbitrary; it reflects research-ethics caution about precipitating illness onset in a vulnerable individual.

Self-medication and prodromal risk

A meaningful clinical concern is self-medication during the prodromal phase of psychotic illness. Some individuals approaching first-episode psychosis experience attenuated symptoms (subclinical perceptual changes, magical thinking, anxiety) and may seek psychedelics — recreationally or through unregulated providers — in an attempt to "process" these experiences. Both clinical literature and Canadian Early Psychosis Intervention services flag this as a concerning pattern. Psychedelic exposure in prodromal patients may contribute to acceleration of, or unmasking of, frank psychotic illness.

This is part of why comprehensive intake screening at every psychedelic-assisted therapy program is non-negotiable.

The psychotic-disorder evidence map for psychedelic-assisted therapy

Standard exclusion across RCTs

Goodwin 2022 — COMP001 psilocybin TRD trial (NEJM): excluded personal or first-degree family history of schizophrenia or other primary psychotic disorder.
Carhart-Harris 2021 — psilocybin vs. escitalopram MDD (NEJM): excluded primary psychotic-disorder history.
Mitchell 2021/2023 — MAPP1 / MAPP2 MDMA-AT for PTSD (Nature Medicine): excluded primary psychotic disorders.
Bogenschutz 2022 — psilocybin for alcohol use disorder (JAMA Psychiatry): excluded primary psychotic disorders.
MAGNUS phase 3 psilocybin program: continues to exclude primary psychotic disorders.

In other words: across nearly every modern psychedelic-assisted therapy RCT, this is a standard exclusion criterion, regardless of indication.

Treatment-resistant schizophrenia and psychedelic-assisted therapy

Despite occasional academic discussion of 5-HT2A pharmacology in schizophrenia, there is no clinically appropriate role for psychedelic-assisted therapy in treatment-resistant schizophrenia. The standard of care remains clozapine + psychosocial intervention, with consideration of long-acting injectables, ECT in selected refractory cases, and rigorous comorbidity management.

Psychotic depression (MDD with psychotic features)

Psychotic depression — major depression with mood-congruent or mood-incongruent psychotic features — is treated with antipsychotic + antidepressant combination, with ECT for severe, urgent, or refractory cases. Psychedelic-assisted therapy is not indicated. Patients diagnosed with TRD who actually have psychotic depression require careful re-assessment before any psychedelic referral.

Substance-induced psychosis history

A history of substance-induced psychotic disorder — including from cannabis, stimulants, or prior hallucinogen use — is itself a meaningful exclusion signal across RCTs. Re-exposure to a similar pharmacological class is not a controlled-risk decision.

For more detail see Ketamine Therapy in Canada, Psilocybin Therapy in Canada, and MDMA-Assisted Therapy in Canada.

Decision framework — psychotic-disorder-specific considerations

For patients or clinicians considering whether psychedelic-assisted therapy is appropriate:

Step	Question	Consequence
1	Personal history of schizophrenia, schizoaffective disorder, schizophreniform, or other primary psychotic disorder?	Yes → near-absolute contraindication for psilocybin and MDMA; ketamine generally not appropriate
2	Personal history of brief psychotic disorder, substance-induced psychotic disorder, or any prior psychotic episode?	Yes → exclusion across most RCTs; clinical judgment required, default to not proceeding
3	First-degree family history (parent, sibling, child) of schizophrenia, schizoaffective, or other primary psychotic disorder?	Yes → standard RCT exclusion; clinical judgment required, default to not proceeding
4	Current attenuated psychotic symptoms (prodromal features)?	Yes → urgent referral to Early Psychosis Intervention service; psychedelic-assisted therapy contraindicated
5	Diagnosed with TRD — is there any unaddressed psychotic-features history?	Yes → re-assess for psychotic depression before any psychedelic referral
6	Substance-induced psychosis (cannabis, stimulants, hallucinogens) in the past?	Yes → exclusion in most RCTs; clinical judgment required, default to not proceeding

Canadian access pathways — and where they don't apply

Comprehensive psychotic-disorder care first

Psychiatric specialist relationship: psychotic disorders require ongoing psychiatrist involvement — primary care alone or psychotherapy alone is not sufficient.
Antipsychotic optimization: first-line second-generation antipsychotics; clozapine for TRS; LAIs as appropriate.
CBT for psychosis and family intervention: provincial mental health services.
Early Psychosis Intervention (EPI) services: every Canadian province has structured EPI programs for first-episode and prodromal patients.
Provincial drug plans cover most antipsychotics including clozapine.

Off-label ketamine for primary psychotic-disorder indications

Not a clinically appropriate indication. Ketamine is not an established treatment for schizophrenia or other primary psychotic disorders, and its NMDA-antagonist mechanism produces psychotomimetic effects that are particularly hazardous in this population.

Spravato in psychotic-disorder populations

The Health Canada Spravato product monograph flags psychotic disorder as a relevant caution. Off-label use in primary psychotic-disorder populations is not supported by current Canadian clinical practice.

Psilocybin SAP and MDMA SAP

Generally not supported for any patient with primary psychotic-disorder history or first-degree family history, given the universal RCT exclusion pattern and mechanistic concerns. ATMA CENA will not typically support SAP applications in these populations.

What the evidence does NOT say

Schizophrenia or psychotic disorders are not currently a treatment indication for psychedelic-assisted therapy in Canada or any other jurisdiction.
Investigation in carefully-screened psychotic-disorder populations is very limited. Whatever academic discussion exists about 5-HT2A pharmacology in schizophrenia does not translate to clinical practice.
First-degree family history exclusion is not a guarantee of harm. It is a research-ethics precaution rooted in genetic risk; it is also clinical-practice precaution. Patients with a family history sometimes feel this is unfair; the rationale is honest precaution, not stigma.
Substance-induced psychotic episodes in a patient's history are not safely "ignored" once resolved; they materially shift risk for re-exposure to a similar pharmacological class.
Psychotic depression is not unipolar TRD. Failure to distinguish them at intake is a meaningful clinical risk.
Self-medication during the prodromal phase is a real-world pattern that early-psychosis services flag. Honest screening protects vulnerable patients from unmasking or accelerating illness.

How ATMA CENA works with patients with personal or family psychotic-disorder history

ATMA CENA's psychotic-disorder-specific pathway:

Comprehensive intake: explicit screening for personal psychotic-disorder history, prior psychotic episodes (including substance-induced), and first-degree family psychotic-disorder history.
Psychiatric coordination: patients with psychotic-disorder diagnosis or active prodromal symptoms are routed to Early Psychosis Intervention services or their existing psychiatrist; ATMA CENA will not enroll patients without resolution of acute clinical concerns.
Honest framing: ATMA CENA will decline to support psilocybin or MDMA SAP applications where there is personal or first-degree family psychotic-disorder history, given the universal RCT exclusion pattern.
No outcome promises about psychedelic-assisted therapy in these populations; no testimonials are used in any ATMA CENA communication.
Supportive referral: patients excluded from a careful clinical pathway are not abandoned — referral and information about evidence-based alternatives (antipsychotic optimization, CBTp, EPI services, clozapine for TRS) is part of the same conversation.

For more detail see Ketamine Therapy in Canada, Psilocybin Therapy in Canada, and MDMA-Assisted Therapy in Canada.

Frequently asked questions

Can I do psilocybin therapy if I have schizophrenia or schizoaffective disorder? No. Personal history of schizophrenia, schizoaffective disorder, or other primary psychotic disorder is a standard exclusion across psilocybin RCTs (Goodwin 2022; Carhart-Harris 2021) and is treated as a near-absolute contraindication in clinical practice. The mechanistic reason is 5-HT2A agonism overlapping with psychotomimetic effects.

Can I do MDMA-AT if I have a psychotic-disorder diagnosis? No. Mitchell 2021/2023 and Mithoefer 2018 excluded primary psychotic disorders, and clinical practice mirrors that exclusion.

Can I do ketamine therapy if I have schizophrenia? Generally no. Ketamine's NMDA-antagonist mechanism produces dissociative and psychotomimetic effects that are particularly hazardous in psychotic-spectrum populations. Most Canadian KAP clinics treat psychotic-disorder history as an exclusion or near-exclusion. The Health Canada Spravato product monograph flags psychotic disorder as a relevant caution.

My parent / sibling has schizophrenia. Can I still do psychedelic-assisted therapy? First-degree family history of schizophrenia or schizoaffective disorder is a standard exclusion criterion across psilocybin and MDMA RCTs. In clinical practice, this is generally treated as a contraindication, not a footnote. Honest screening at intake is essential, and a careful psychiatric assessment is appropriate before any decision.

I had one psychotic episode years ago — does that still count? Yes. A prior psychotic episode, including substance-induced psychotic disorder, is a meaningful exclusion signal across RCTs and clinical practice. It does not mean nothing can ever be considered, but it does mean honest screening, psychiatric assessment, and a default toward not proceeding with psilocybin or MDMA.

I think I might be in a prodromal phase — perceptual changes, magical thinking. What should I do? Please seek urgent assessment from your provincial Early Psychosis Intervention service or a psychiatrist. Self-medicating with psychedelics during the prodromal phase is a known concerning pattern and may accelerate or unmask psychotic illness. Psychedelic-assisted therapy is contraindicated.

I have treatment-resistant depression — could I have psychotic depression instead? This is worth careful re-assessment. Psychotic depression (MDD with psychotic features) is treated with antipsychotic + antidepressant combination, with ECT for severe or refractory cases. Psychedelic-assisted therapy is not indicated. A patient diagnosed with unipolar TRD who actually has psychotic depression deserves accurate diagnosis before any psychedelic referral.

What about treatment-resistant schizophrenia? The gold-standard treatment is clozapine, with rigorous monitoring. Despite occasional academic discussion of 5-HT2A pharmacology in schizophrenia, there is no clinically appropriate role for psychedelic-assisted therapy in TRS at this time.

Can I share my psychotic-disorder history honestly with the clinical team? Yes — please do. Personal and family psychotic-disorder history is critical safety information; honest disclosure protects you. ATMA CENA's clinical team is non-judgmental and uses this information to make appropriate clinical decisions, not to stigmatize.

Is this exclusion forever? For psilocybin and MDMA in primary psychotic-disorder populations or first-degree family history, the current evidence base does not support inclusion, and that's unlikely to change in the near term. Future research in carefully-screened, controlled settings may modify what's possible — but not soon, and not in general clinical practice.

Sources

Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
Carhart-Harris R, Giribaldi B, Watts R, et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15):1402-1411. PMID: 33852780.
Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
Mitchell JM, Ot'alora G M, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37709999.
Bogenschutz MP, Ross S, Bhatt S, et al. (2022). Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 79(10):953-962. PMID: 36001306.
Krystal JH, Karper LP, Seibyl JP, et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry, 51(3):199-214. PMID: 8122957.
Health Canada — Spravato (esketamine) Product Monograph: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
Norman RMG, Lecomte T, Addington D, Anderson E. (2017). Canadian Treatment Guidelines on Psychosocial Treatment of Schizophrenia in Adults. Canadian Journal of Psychiatry, 62(9):617-623. PMID: 28886669.
Remington G, Addington D, Honer W, et al. (2017). Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Canadian Journal of Psychiatry, 62(9):604-616. PMID: 28703015.
Addington D, Anderson E, Kelly M, et al. (2017). Canadian Practice Guidelines for Comprehensive Community Treatment for Schizophrenia and Schizophrenia Spectrum Disorders. Canadian Journal of Psychiatry, 62(9):662-672. PMID: 28886671.
Public Health Agency of Canada — Mental Illness Surveillance: https://health-infobase.canada.ca/mental-illness/
Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
EPION (Early Psychosis Intervention Ontario Network) clinical resources: https://www.epion.ca/

Last updated: 2026-05-06

Schizophrenia and Psychotic Disorders — Why Psychedelic-Assisted Therapy Is Generally Contraindicated